Business Wire

Forrester Unveils Top 10 Emerging Technologies For 2025; AI Innovation Shifts From Experimentation To Business Imperative

6.5.2025 15:00:00 CEST | Business Wire | Press Release

Share

As generative AI evolves into agentic AI, automation becomes more sophisticated, and emerging technologies shift to large-scale deployment, firms will no longer be experimenting with AI by the end of 2025 — they will be racing to keep up with AI’s acceleration. However, given ongoing geopolitical volatility, making the right technology investment decisions will be a key lever for business growth and competitive advantage. Forrester’s (Nasdaq: FORR) research, The Top 10 Emerging Technologies In 2025, highlights new technologies that empower leaders to drive AI-led innovation while ensuring long-term resilience.

The research categorizes the top 10 emerging technologies by their impacts over short-term, mid-term, and long-term benefits horizons to help enterprises and leaders prioritize their investments. An overview of the top findings is as follows:

Emerging technologies that will offer significant benefits to enterprises within the next two years by balancing AI acceleration with security needs include:

  • IoT security. As cyber threats increase, IoT security technologies will be critical to strengthening defenses for critical data and connected devices. Businesses with high technology integration will see the biggest benefits from IoT security.
  • Synthetic data. New to Forrester’s emerging technologies list this year,this technology enhances AI model training while improving trust and privacy. With regulators encouraging organizations to adopt synthetic data to minimize risk, industries including financial services, insurance, healthcare, and the public sector will benefit the most.

Mid-term emerging technologies that will deliver benefits to enterprises in the next two to five years given their real-world complexity include:

  • Agentic AI. The immediate potential of this technology is increased flexibility and adaptability to automate specific business processes. Although early examples of AI agents are promising and offer autonomous decision-making, this technology still requires stronger accuracy, trust, and coordination to become mainstream.
  • GenAI for visual content. This technology is changing the way companies create and deploy photorealistic images, videos, and motion graphics. GenAI for visual content is poised to make the biggest impact in marketing, advertising, retail, and e-commerce sectors, delivering immersive and personalized preferences, and boosting consumer satisfaction.

The emerging technology that will take at least five more years to deliver tangible value for enterprises:

  • Humanoid robots. This is the first year that this emerging technology has appeared on the list.GenAI’s rapid advancement and decreasing hardware costs are driving the advancement of humanoid robots — autonomous robots that resemble humans in appearance and functionality and are equipped with advanced sensors, AI, and actuators to perform tasks. However, challenges including high research and development costs, and complexities surrounding robot integration into existing workflows and infrastructure will hinder their widespread adoption.

“As AI becomes ubiquitous, business and technology leaders should prioritize investments that will deliver the greatest impact for their organizations in terms of driving business growth, innovation, and competitive advantage,” said Sharyn Leaver, chief research officer at Forrester. “Despite global uncertainty, AI’s rapid acceleration will continue. Enterprises that strategically balance AI innovation with risk mitigation will be ones that successfully thrive and achieve sustainable growth.”

Resources:

  • Register for a complimentary webinar to learn about Forrester’s 10 top emerging technologies for 2025 and how these innovations apply across industries.
  • Register to attend Forrester’s 2025 Technology & Innovation Summits in North America, EMEA, and Asia Pacific.

About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250506106586/en/

Contacts

Ira Kantor
ikantor@forrester.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye